Cocaine Hydrochloride

Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market in the first half of the 2025 calendar yearNEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted INBS’ Intelligent Fingerprinting Drug Screening System. Princebuild has made a strategic decision to move from saliva testing to fingerprint drug screening in order to implement a more streamlined, in-house solution that prioritizes efficiency, accuracy, and respect for employee privacy. Princebuild, an established construction company in Peterborough, Cambridgeshire, UK and its surrounding areas, has integrated INBS' fingerprint sweat-based technology to enhance safety and compliance across its workforce. The system's simplicity, ease of use, and shorter detection window will enable Princebuild to conduct fast, reliable testing while respecting employees' personal lifestyles. "By adopting Intelligent Bio Solutions fingerprint sweat-based system, we have transformed our approach to workplace testing," said Cheryl Browne, Human Resources Support Manager at Princebuild. "We wanted a method that ensured safety in our workplace without feeling like we were policing our employees' lifestyles. The simplicity and efficiency of this solution aligns with our company values." Princebuild joins other leading construction companies that utilize INBS’ innovative drug-testing technology, including Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. Ltd. These companies employ INBS’ technology to proactively address substance misuse in the workplace by focusing on ensuring employees are fit for duty at the time of testing. INBS’ Intelligent Fingerprinting Drug Screening System allows organizations to implement an accurate and efficient testing protocol that meets the needs of the modern workforce. With its ability to detect multiple substances simultaneously and provide rapid results, the system eliminates many challenges associated with traditional testing methods, allowing businesses like Princebuild to focus on cultivating safer, more productive workplaces. The Company has over 400 accounts across 19 countries. Its Drug Testing Solution is currently being utilized across multiple industries, including construction, mining, manufacturing and engineering, transport and logistics, drug treatment, law enforcement, and forensics. With recent FDA 510(k) submission in December of 2024 and entry into the US market planned for the first half of calendar year 2025, INBS is capitalizing on the rapidly growing drug screening products market. About Princebuild Princebuild Limited has cared for, maintained, and built properties since 1971. The company specializes in delivering diverse construction services through six key divisions: construction, small works, insurance, maintenance, building services, and commercial interiors. Over the years, Princebuild has expanded its operations to serve the entire East of England and provides national coverage for larger projects. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com

MONDAY, Dec. 23, 2024 -- Substance use among adolescents has continued to hold steady at lowered levels for the fourth year in a row, according to the U.S. National Institutes of Health (NIH)-funded Monitoring the Future Survey. The Monitoring the Future survey, conducted by researchers at the University of Michigan in Ann Arbor, included 24,257 surveys (February through June 2024) from students in eighth, 10th, and 12th grades, enrolled across 272 public and private schools in the United States. Results showed alcohol use remained stable for eighth graders, with 12.9 percent reporting use in the previous 12 months, and declined for 10th and 12th graders (26.1 percent in 2024 versus 30.6 percent in 2023 for 10th grade, and 41.7 versus 45.7 percent, respectively, for 12th grade). Nicotine vaping remained steady for eighth graders (9.6 percent) and 12th graders (21.0 percent) and declined among 10th graders to 15.4 percent reporting use in the previous 12 months versus 17.6 percent in 2023. Nicotine pouch use remained stable for eighth graders (0.6 percent), but increased among the two older grades (10th grade: 3.4 percent versus 1.9 percent in 2023; 12th grade: 5.9 and 2.9 percent, respectively). Eighth and 10th graders reported stable cannabis use (7.2 and 15.9 percent, respectively), while past 12-month cannabis use declined among 12th graders (25.8 percent versus 29.0 percent in 2023). Use of any other illicit drug (past-year use of cocaine, heroin, and misuse of prescription drugs) declined among eighth graders (3.4 percent versus 4.6 percent in 2023) and remained stable for 10th and 12th graders (4.4 and 6.5 percent, respectively). Abstaining from marijuana, alcohol, and nicotine in the past 30 days remained stable for eighth graders (89.5 percent) and increased for the two older grades (10th: 80.2 percent versus 76.9 percent in 2023; 12th: 67.1 percent versus 62.6 percent in 2023). "This trend in the reduction of substance use among teenagers is unprecedented," Nora D. Volkow, M.D., director of NIH National Institute on Drug Abuse, said in a statement. "We must continue to investigate factors that have contributed to this lowered risk of substance use to tailor interventions to support the continuation of this trend." More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.